Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammanorm pump versus manual syringe administration in adults with primary immunodeficiency
ISRCTN55938644Phase 4Completed
- Sponsor
- Octapharma
- Start
- Jun 2015
01
Overview
Phase 4, randomised, open-label trial of ALYGLO in Immunogenetic disorder (2 arms), sponsored by Octapharma. Primary endpoint: Patient satisfaction by Life Quality Index. Started Jun 2015; status: completed.
02
Drugs
ALYGLO
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on ISRCTN55938644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55938644.